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Abstract
Background: Increasing attention has been focused on inulin and levan-type oligosaccharides,
including fructosyl-xylosides and other fructosides due to their nutraceutical properties. Bacillus
subtilis levansucrase (LS) catalyzes the synthesis of levan from sucrose, but it may also transfer the
fructosyl moiety from sucrose to acceptor molecules included in the reaction medium. To study
transfructosylation reactions with highly active and robust derivatives, cross-linked enzyme
aggregates (CLEAs) were prepared from wild LS and two mutants. CLEAs combine the catalytic
features of pure protein preparations in terms of specific activity with the mechanical behavior of
industrial biocatalysts.
Results: Two types of procedures were used for the preparation of biocatalysts from purified wild
type LS (WT LS) B. subtilis and the R360K and Y429N LS mutants: purified enzymes aggregated with
glutaraldehyde (cross-linked enzyme aggregates: CLEAs), and covalently immobilized enzymes in
Eupergit C®. The biocatalysts were characterized and used for fructoside synthesis using xylose as
an acceptor model. CLEAs were able to catalyze the synthesis of fructosides as efficiently as soluble
enzymes. The specific activity of CLEAs prepared from wild type LS (44.9 U/mg of CLEA), R360K
(56.5 U/mg of CLEA) and Y429N (1.2 U/mg of CLEA) mutants were approximately 70, 40 and 200-
fold higher, respectively, than equivalent Eupergit C® immobilized enzyme preparations (U/mg of
Eupergit), where units refer to global LS activity. In contrast, the specific activity of the free enzymes
was 160, 171.2 and 1.5 U/mg of protein, respectively. Moreover, all CLEAs had higher thermal
stability than corresponding soluble enzymes. In the long term, the operational stability was affected
by levan synthesis.
Conclusion: This is the first report of cross-linked transglycosidases aggregates. CLEAs prepared
from purified LS and mutants have the highest specific activity for immobilized fructosyltransferases
(FTFs) reported in the literature. CLEAs from R360K and Y429N LS mutants were particularly
suitable for fructosyl-xyloside synthesis as the absence of levan synthesis decreases diffusion
limitation and increases operational stability.
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Background
Bacillus subtilis LS is a fructosyltransferase (FTF) synthesiz-
ing levan, a high molecular weight fructose polymer, by
using sucrose as a donor and acceptor of the transferred
fructosyl moiety (transfructosylation reaction). In general
FTFs can also transfer the fructose residue either to water
(hydrolysis reaction) or to an acceptor molecule other
than the sucrose or fructan present in the reaction
medium (acceptor reaction) [1]. Several applications have
been developed for levan, such as an anti-inflammatory
agent against skin irritation and as a cell-proliferative
agent [2]. However, much attention has been focused on
inulin and levan-type oligosaccharides, including fructos-
ides containing xylose, galactose, glucose and mannose
due their prebiotic properties [3,4] as well as their poten-
tial applications as alternative low caloric sweeteners [5].
An additional application of FTFs is derived from its
potential to fructosylate a variety of molecules of indus-
trial interest, particularly for food and pharmaceutical
applications [6-8]. Nevertheless, considering its broad
reaction specificity, Bacillus subtilis LS mutants with
reduced levan synthesis activity are required to avoid pol-
ymer synthesis and to increase fructosides.
One of the greatest challenges in industrial biocatalyst
development is the design of highly active and robust
derivatives that are stable over a broad range of opera-
tional pH and temperatures, a requirement that is strongly
associated with the immobilization method [9]. Carrier-
bound enzymes traditionally have been the first option
for biocatalyst development, even when the inert supports
often account for the majority of the biocatalyst mass. In
such cases, the concomitant reduction in specific activity
results in low volumetric and space-time yields when
applied in continuous reactors [10]. A major advance-
ment in biocatalysis is the development of cross-linked
enzyme crystals and aggregates (CLECs and CLEAs) that
act as biocatalysts that combine the features of pure pro-
tein preparations in terms of specific activity and the
behavior of biocatalyst particles [9,11-14]. CLECs and
CLEAs have been shown to be useful for the development
of biocatalysts based on a wide variety of enzymes, includ-
ing glucose isomerase (D-xylose ketol-isomerase,
E.C.5.3.1.5) [15], hydrolases, lyases and oxidoreductases
[9,12]. Although CLECs generation requires the crystalli-
zation of the enzyme prior to cross-linking, CLEAs prepa-
ration from preformed aggregates of purified enzymes
constitutes a simpler method with specific activities com-
parable to CLECs [13]. Moreover, they are particularly
advantageous over CLECs in which substrate or products
may induce internal diffusional resistances that limit the
reaction rate. LS is an interesting option to investigate the
design of biocatalysts in the form of CLEAs due to their
feasibility for purification as well as their potential for the
fructosylation of bioactive compounds.
In this work, we explore xylose fructosylation as a model
of acceptor reaction using CLEAs produced from LSs. For
this purpose, purified WT LS, R360K and Y429N LS
mutants were aggregated and cross-linked. These enzymes
were also subjected to traditional immobilization onto
Eupergit C® in order to compare the properties and effi-
ciency of both biocatalysts. The properties of WT LS as
well as the two mutants have been previously reported
[16,17] and are summarized in Table 1. We previously
demonstrated that the synthesis of levan displayed by WT
LS and R360K (a variant bearing a similar specific activity)
can be considerably reduced in the presence of high affin-
ity acceptors such as xylose and maltose, which also
reduces their hydrolytic activity [17]. Additionally, Y429N
has been reported to be a non-levan-synthesizing mutant
that exhibits a 50% reduction in its sucrose hydrolytic
Table 1: Specific activity and reaction specificity of B. subtilis WT LS and selected mutants
Reaction specificity(%): sucrose 
(120 g/L)
Reaction specificity (%): sucrose (120 g/L)/
xylose (120 g/L)
Enzyme Specific activity
(U/mg protein)
Hydrolysis Trans-
fructosylation
Hydrolysis Trans-
fructosylation 
to sucrose
Trans-
fructosylation 
to xylose
Product 
synthesized 
from sucrose 
(120 g/L)
WT LS 160.5 (± 6.0) 52. 547.5 21.3 18.1 60.6 Levan with 
molecular weight 
bimodal 
distribution
R360K 171.2 (± 7.0) 88.3 11.7 37.0 5.3 57.7 Oligosaccharides 
and low amounts 
of high molecular 
weight levan
Y429N 1.5 (± 0.9) 97.3 2.7 49.3 9.6 41.1 Oligosaccharides
Invertase 878.3 (± 6.8) 98.6 1.4 0.0 0.0 0.0 -
a Reaction specificity: percentage of sucrose used for hydrolysis and transfructosylation to sucrose or to xylose. Hydrolysis, transfructosylation and 
products were determined after 80% sucrose conversion. Data extracted from [17], except for invertase, analyzed in this work.BMC Biotechnology 2009, 9:68 http://www.biomedcentral.com/1472-6750/9/68
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activity in acceptor reactions. Therefore, the appropriate
enzyme and reaction conditions can be defined for fructo-
sylation reactions with reduced polymer synthesis as well
as sucrose hydrolysis, minimizing diffusional limitations
by levan.
Results and Discussion
CLEAs preparation
CLEAs were designed to obtain a constrained but suffi-
ciently large levansucrase arrangement to allow for sub-
strate and product diffusion. For this purpose the effect of
ammonium sulfate, glutaraldehyde and protein concen-
trations on CLEAs activity was explored. After solvent
accessibility analysis using the ASAView algorithm, it was
found that B. subtilis LS contains 40 lysine residues with
their ε-amino groups exposed to the solvent, including
K114, 185 and 363, which are positioned at the rim of the
active site. It is therefore important to define proper reac-
tion conditions with glutaraldehyde to avoid excessive
cross-linking, as glutaraldehyde mainly reacts with ε-
amino groups followed by α-amino, guanidinyl, second-
ary amino, and hydroxyl groups at near neutral pH [18].
As shown in Figure 1, the highest activity was obtained in
all LS-CLEAs when a protein:glutaraldehyde molar ratio
of 1:263 (0.2% v/v glutaraldehyde) was used. An impor-
tant decrease in activity as a result of aggregation was
observed for WT LS and R360K CLEAs at glutaraldehyde
concentrations higher than 0.2% (v/v). Interestingly, high
glutaraldehyde concentrations did not have any effect on
Y429N-CLEAs activity, and the immobilized enzyme
retained around 90% of soluble enzyme activity. This
mutant has a low specific rate and sucrose affinity (kcat
and Km of 6 s-1 and 320 mM, respectively, compared to
165 s-1 and 8 mM of the WT LS [17]). These results suggest
that WT LS- and R360K-CLEAs undergo diffusional limi-
tations. This could be overcome either by reducing the
aggregate particle size, as reported for trypsin-CLEAs [19],
where 90% of free trypsin activity was recovered after
decreasing the biocatalyst size, or by reducing the amount
of enzyme used in the design of the CLEAs. As far as spe-
cific activity is concerned, the highest value was obtained
with R360K-CLEAs, followed by WT and Y429N-CLEAs,
when CLEAs were prepared with 60% ammonium sulfate,
0.2% glutaraldehyde and 4 mg protein/mL. These results
are shown in Table 2, where it may be observed that even
in the cases of low immobilization efficiency the specific
activity of the LSs-CLEAs were the highest reported for an
immobilized transglycosylase, either glucosyltransferase
(GTF) or FTF, due to the nature of the biocatalyst structure
(the proportion of glutaraldehyde in the purified enzymes
is negligible) [20,21].
In terms of particle size, the preparation procedure plays
an important role, as shown in Figure 2. Indeed, although
aggregates have an average size of 15 μm, they tend to
form larger aggregates when centrifuged or when residual
glutaraldehyde is not washed off.
Immobilization on Eupergit C®
Immobilization of FTFs and GTFs on various supports as
Eupergit®, hydroxyapatite and alginates has been previ-
ously reported for oligosaccharides and polymer synthesis
[20-24]. To compare the properties and efficiency of bio-
catalysts obtained by covalent immobilization on a given
support or by aggregation, WT LS and its mutants were
also immobilized on Eupergit C®. A two-step binding
mechanism for the Eupergit C® immobilization process
has been proposed. It is assumed that, in the first step, the
enzyme is physically adsorbed on the carrier via hydro-
phobic interactions. This brings the amino and thiol
groups on the surface of the enzyme in close proximity to
the oxirane groups of the carrier. In the second step, they
Table 2: Characterization of Levansucrases-CLEAs
Enzyme Aggregation yielda (%) LS-CLEAs
U/mg of CLEA
WT LS 28 (± 4.2) 44.9 (± 6.9)
R360K 33 (± 4.1) 56.5 (± 7.2)
Y429N 80 (± 7.5) 1.2 (± 0.1)
a Aggregation yield is defined as the activity recovered in CLEAs when 
compared with the total activity load of soluble enzyme in the 
experiment (100%).
Effect of glutaraldehyde concentration on relative CLEAs  activity Figure 1
Effect of glutaraldehyde concentration on relative 
CLEAs activity. WT-CLEAs (black circles), R360K-CLEAs 
(black inverted triangles) and Y429N-CLEAs (black squares). 
The effect of cross-linking was examined in the range of 0.2 
to 1% glutaraldehyde (v/v), using 1 mg/mL of purified 
enzymes. Activity after cross-linking was compared to the 
activity of soluble enzymes, which was taken as 100%. Results 
represent the mean (± SD) of five experiments.BMC Biotechnology 2009, 9:68 http://www.biomedcentral.com/1472-6750/9/68
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react with the oxirane groups through nucleophilic attack
[25].
The immobilization conditions, including protein con-
centration, pH and immobilization time, were varied for
the R360K mutant, which displayed the highest specific
activity. More protein was loaded at pH 7.0 than at pH 6.0
after 38 h of immobilization. In addition, the highest
R360K-Eupergit C® specific activity was found at a protein/
support ratio of 20/1 (mg protein/g support). A summary
of the immobilization procedure on Eupergit C® and the
results are shown in Table 3. The specific activity of
R360K-CLEAs is higher when compared to the covalent
biocatalyst prepared in this study or to previously
reported transglycosidases biocatalysts immobilized on
the same support [20,21]. Therefore, during biocatalyst
design using stable and readily purified enzymes, such as
B. subtilis LS, it is important to consider the remarkable
difference between specific activities of the biocatalysts
prepared using inert supports and those obtained as
CLEAs. In the case of LS, the latter was about 70, 200 and
40-fold higher for WT LS, Y429N and R360K respectively
than the corresponding Eupergit C® immobilized enzyme
preparations (Tables 2 and 3).
Transfructosylation reactions with CLEAs
CLEAs activity was assayed for both levan (or oligosaccha-
rides) and acceptor reactions performed in the presence of
sucrose and sucrose/xylose respectively. As expected, WT-
CLEAs activity drastically decreases after a few minutes
when sucrose acts both as a donor and an acceptor of the
fructosyl moiety. It is clear that as the enzyme catalyzes
the synthesis of levan, the polymer formed inside the bio-
catalyst introduces increasing diffusional restrictions as
demonstrated by the sudden reduction of sucrose conver-
sion during the reaction (Figure 3A). Although R360K was
first reported as a non polymer-producing mutant [16],
slight residual polymer-synthesizing activity was retained
under our experimental conditions [17]. It is therefore
likely that the low amount of high molecular weight levan
synthesized by this mutant is enough to introduce inter-
nal diffusional resistance in the biocatalyst, particularly
when accumulated after a certain operation time or
repeated reaction cycles. In contrast, it may also be
Images of B. subtilis levansucrase R360K mutant CLEAs Figure 2
Images of B. subtilis levansucrase R360K mutant CLEAs. A) CLEAs images obtained immediately after quenching the 
cross-linking reaction; B) CLEAs washed and centrifuged after cross-linking reaction and C) CLEAs after 48 h of quenching; in 
this last case, CLEAS were not washed. Digital images were collected in phase contrast mode with a 40×, NA 0.75, Ph 2 objec-
tive.
Table 3: Characterization of WT, R360K and Y429N LS immobilized on Eupergit C®.
Enzyme mg LS/g Eupergit C® Immobilization yield (%)d U LSs/mg EupergitC®
WT LSa 6.8 59 0.64
Y429Na 7.8 55 0.006
R360Ka 7.1 60 0.74
R360Kb 9.3 58 0.93
R360Kc 18.8 51 1.64
a Immobilization at pH 6.0, during 38 h.b Immobilization at pH 7.0, during 38 h. Immobilization at pH 7.0, during 72 h. In all cases 10 mg of enzyme 
were contacted per g of Eupergit C®, except for (c), where 20 mg were used.dYield is defined as the activity recovered in Eupergit C® when 
compared with the total activity load of free enzyme in the assay (100%). Eupergit is reported in dry basis.BMC Biotechnology 2009, 9:68 http://www.biomedcentral.com/1472-6750/9/68
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observed in Figure 3A that sucrose conversion by Y429N,
a highly hydrolytic and non-levan synthesizing mutant,
continued to increase during the course of the experiment.
It has been reported that D-xylose is a good acceptor and
forms  β-D-fructofuranosyl-α-D-xylopyranoside when
using LS from B. subtilis NCIMB 11871 [5]. Additionally,
we previously observed that transfer onto sucrose (levan
production) is nearly avoided when xylose is added to the
reaction medium [17]. We therefore selected xylose as an
acceptor model for transfructosylation reactions.
It was also found that all LS-CLEAs catalyzed fructosyl-
xyloside production as efficiently as soluble enzymes.
Fructosyl-xyloside production from soluble R360K and
WT/R360K/Y429N-CLEAs is shown in Figure 3B. There-
fore, efficient CLEAs design for fructosylation depends
mainly on the selection of adequate LSs and the optimiza-
tion of reaction conditions to avoid levan synthesis.
The resulting fructosyl-xyloside was purified, quantified
by HPLC and its structure elucidated by 1H and 13C NMR
spectroscopy, as well as by 2DNMR spectroscopy. It was
found that B. subtilis WT LS forms β-D-fructofuranosyl-(2-
1)-α-D-xylopyranoside (Figure 4) when D-xylose acts as
acceptor of the sucrose fructosyl moiety, which corre-
sponds to published reports for B. subtilis NCIMB 11871
LS [5]. The NMR assignations corresponding to the β-D-
fructofuranosyl-(2-1)-α-D-xylopyranoside structure are as
follows:
1H NMR (400 MHz, D2O) 5.3 (d, J1,2 3.6 Hz, 1H, H-1), 4.2
(d, J3,4, 8.8 Hz, 1H, H-3'), 4.09 (t, J4,3 8.4 J4,5 8.4 Hz, 1H,
H-4'), 3.84–3.88 (m, 1H, H-5'), 3.77–3.81 (2d, J6a, 5 = J6b,
5 2.4 Hz, 2H, 6a-H', 6b-H'), 3.63–3.66 (m, 1H, H-4),
3.66–3.69 (m, 4H, H-5, 2H6a, b'), 3.57–3.61 (m, 1H, H-
3), 3.50 (dd, J2,1 3.6, J2,3 9.6,1H, H-2).
13 C NMR (400 MHz, D2O) 105.9 (C-2'), 94.5 (C-1), 83.7
(C-5'), 78.3 (C-3'), 75.3 (C-4'), 75.04 (C-4), 73.3 (C-2),
71.5 (C3), 64.07 (C-5), 64.04 (C-1'), 63.0 (C-6').
CLEAs' thermal and operational stability
CLEAs' residual activity after a 1-h incubation at different
temperatures in the absence of sucrose was measured with
soluble WT LS and the R360K mutant, as well as with the
corresponding CLEAs and Eupergit C®immobilized
enzyme preparations. No significant differences in activity
were observed, demonstrating that LS and its R360K
mutant display the same thermal stability aggregated in
CLEAs than when covalently bound to Eupergit C® (Figure
5). However, when sucrose conversion was measured after
β-D-fructofuranosyl-(2-1)-α-D-xylopyranoside structure Figure 4
β-D-fructofuranosyl-(2-1)-α-D-xylopyranoside struc-
ture. The fructosyl-xyloside was purified by HPLC and ana-
lyzed by 1H and 13C NMR spectroscopy, as well as by 
2DNMR spectroscopy.
Reaction evolution during oligosaccharides/levan (A) and  fructosyl-xyloside (B) synthesis Figure 3
Reaction evolution during oligosaccharides/levan (A) 
and fructosyl-xyloside (B) synthesis. Free R360K (rhom-
bus), WT-CLEAs (circles), R360K-CLEAs (inverted triangles) 
and Y429N-CLEAs (squares). Black symbols indicate sucrose 
consumption, while open symbols represent the fructosyl-
xyloside synthesis. WT and R360K-CLEAs undergo diffu-
sional restrictions when sucrose is used both as donor and 
acceptor due to the levan synthesis (A), while, in the pres-
ence of xylose, all LS-CLEAs synthesize efficiently the fructo-
syl-xyloside (B). Reactions for oligosaccharides/levan and 
fructosyl-xyloside synthesis were carried out with 0.1 and 0.5 
U/mL of enzymatic activity respectively. Results represent 
the mean (± SD) of three experiments.BMC Biotechnology 2009, 9:68 http://www.biomedcentral.com/1472-6750/9/68
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consecutive 3-h batch-cycles, it was found that the R360K-
and Y429N-CLEAs were more stable than WT LS-CLEAs
(Figure 6A).
The apparent activity loss after each reaction cycle is most
likely due to product accumulation inside the biocatalyst
acting to reduce the global reaction rate and block the
intra particle structure of the biocatalysts. Evidence of this
phenomenon was found when fructose was identified as
a product of acid hydrolysis of deactivated CLEAs (results
not shown). Again, Y429N-CLEAs was the more stable
biocatalyst, thus complete inhibition of polymer synthe-
sis is required for the maximal biocatalyst operational sta-
bility. However, invertase from baker's yeast, which can be
considered a fructosidase with little transfructosidase
activity is not able to synthesize fructosyl-xyloside
(Table 1).
Whereas the activity loss in R360K-CLEAs was about 60%
after 10 reaction cycles, Eupergit C®-R360K retained about
80%. However, we observed that the activity reduction
after each reaction cycle reached a nearly constant sucrose
conversion in the last five cycles, indicating that at this
time, the residual enzyme is no longer the subject of mass
diffusional restrictions and remains stable in subsequent
reactions (Figure 6B). For the same reasons, a drastic loss
of activity was also observed for WT LS-Eupergit C®. Nev-
ertheless, even considering R360K-CLEAs activity loss
after 10 reaction cycles, its specific activity is still higher
than that of the R360K-Eupergit C® preparation.
Conclusion
This is the first report of cross-linked transglycosidases
aggregates. We have demonstrated that CLEAs are able to
catalyze the synthesis of oligofructosides as efficiently as
soluble enzymes and display a thermal stability compara-
ble to covalent immobilized enzymes on inert supports.
Due to its nature, the LS-CLEAs specific activity reported
here is the highest reported for FTFs and GTFs. Moreover,
R360K-Eupergit C® specific activity is the highest com-
pared to other FTFs and GTFs immobilized on this sup-
port. These biocatalysts are particularly suitable for
fructoside synthesis, here demonstrated for β-D-fructo-
furanosyl-(2-1)-α-D-xylopyranoside production. Reduc-
tion of particle size as well as alternative cross-linking
conditions should be explored if further reductions in
CLEAs diffusional limitations.
Residual activity of CLEAs and Eupergit immobilized enzyme  preparations of levansucrase and R360K mutant after incuba- tion at several temperatures Figure 5
Residual activity of CLEAs and Eupergit immobilized 
enzyme preparations of levansucrase and R360K 
mutant after incubation at several temperatures. 
Residual activity was measured after incubation of 2 mg/mL 
of all preparations at the indicated temperature. Soluble 
levansucrase is included as a control. Results represent the 
mean (± SD) of three experiments.
Operational stability of LSs-CLEAs (A) and Eupergit C®  immobilized enzyme preparations (B) Figure 6
Operational stability of LSs-CLEAs (A) and Eupergit 
C® immobilized enzyme preparations (B). WT-CLEAs 
(black circles), WT LS-Eupergit C®(open circles), R360K-
CLEAs (black inverted triangles), R360K-Eupergit C® (open 
inverted triangles) and Y429N-CLEAs (black squares). 
Sucrose conversion in reactions containing 4 U/mL of initial 
enzymatic activity, 120 g/L of sucrose and 120 g/L of xylose 
was measured after each 3 h batch-reaction cycle. Sucrose 
conversion after the first cycle was around 81% (± 7.3) for all 
CLEAs. R360K-CLEAs are included in both figures. Results 
represent the mean (± SD) of three experiments.BMC Biotechnology 2009, 9:68 http://www.biomedcentral.com/1472-6750/9/68
Page 7 of 8
(page number not for citation purposes)
Methods
Materials
Sugars and invertase (β-fructofuranosidase, EC 3.2.1.26,
Grade VII from baker's yeast) were purchased from Sigma
Chemical (St. Louis, MO). The electrophoresis reagents
were from Bio-Rad Laboratories (CA). All buffer salts were
from JT Baker Co. (Phillipsburg, NJ, USA). Eupergit C® was
purchased from Röhm Pharma (Darmstadt, Germany)
and glutaraldehyde (50%) was from Electron Microscopy
Sciences (Fort Washington, PA, USA).
Bacterial strain, growth conditions and LS purification
E. coli BL21 [E. coli F- ompT hsdSB(rB-mB)gal dcm (DE3)]
transformants were grown, recovered and broken as previ-
ously reported [17]. WT and mutants from LS were puri-
fied by ion exchange chromatography as previously
described [26].
Protein determination
Protein concentration was determined using the Bradford
method (Bio-Rad protein assay) using bovine serum albu-
min (Albumin fraction V, Sigma Chemical, St. Louis, MO)
as the protein standard.
Activity Assay
Initial reaction rates from free levansucrases, CLEAs and
Eupergit C® immobilized enzyme preparations were meas-
ured by following the reducing power released from 120
g/L of sucrose in pH 6.0, 50 mM sodium phosphate buffer
at 37°C, using the 3,5-dinitro-salicylic acid method
(DNS). One unit of enzyme activity was defined as the
amount of enzyme releasing one μmol of glucose equiva-
lent per min. The measured activity corresponds in all
cases to global LS activity, as it includes released reducing
sugars both by transfructosylation (glucose) and hydroly-
sis (fructose and glucose) activities. Hydrolysis and trans-
fructosylation ratios were determined by specific
quantification of glucose and fructose by HPLC.
CLEAs preparation
Cross-linking optimization reactions were carried out
after precipitation of the purified proteins with 60% w/v
ammonium sulfate, pH 7.0, 0.1 M sodium phosphate
buffer for 30 min; the effect of cross-linking with glutaral-
dehyde was explored in the 0.2 to 1% concentration range
in a total volume of 100 μL for a purified enzyme concen-
tration of 1 mg/mL, while 0.2% glutaraldehyde was used
when the protein concentration was varied from 1 to 6 mg
protein/mL for 30 minutes at 15°C; after cross-liking the
mixture was quenched with 900 μL of 50 mM sodium
phosphate buffer, pH 6.0.
Quenched samples were assayed for enzyme activity. A
sample was withdrawn from the resulting suspension,
which contains both CLEAs and residual free enzyme, and
assayed for activity. Afterwards, another aliquot was with-
drawn from the suspension, and the CLEAs were removed
via centrifugation to obtain activity only from the free
enzyme. The difference in activities between the two sam-
ples is the CLEAs activity. This approach is the most accu-
rate way of determining the activity of the CLEAs, without
having to wash and redisperse, which will increase clot-
ting and thereby mass-transport limitations [10].
Reactions using sucrose both as a donor and as acceptor
were carried out with an enzymatic activity of 0.1 U/mL in
a medium containing 120 g/L of sucrose in pH 6.0, 50
mM sodium phosphate at 37°C. CLEAs preparation, as
well as the activity assays were performed five times.
Immobilization of WT LS and R360K and Y429N mutants 
onto Eupergit C®
One gram (dry weight) of Eupergit C® (average particle
size distribution 100–200 μm, approximate pore diame-
ter 0.1–2.5 μm and specific surface 10–20 m2/g) and 10 or
20 mg of purified enzymes were mixed and shaken for 38
or 72 h respectively at 20°C at pH 6.0 or 7.0, in 1 M
sodium phosphate buffer. The Eupergit C® beads were
recovered by filtration and washed with pH 6.0, 50 mM
sodium phosphate buffer (6 × 10 mL). The recovered
immobilized enzyme preparations as well as their super-
natants were assayed for activity as previously described.
The quantity of unbound protein was determined using
the Bradford method.
Fructosyl-xyloside production
Fructosyl-xyloside synthesis was carried out with an
enzyme or biocatalyst concentration adjusted to 0.5 U/mL
activity in reactions containing 120 g/L of sucrose and 120
g/L of xylose at pH 6.0 and 37°C. Xylose, fructose, glu-
cose, sucrose and fructosyl-xyloside were quantified by
HPLC in a Waters 600E system controller (Waters Corp.
Milford, MA) equipped with a refractive index detector
(Waters 410), and a Carbohydrate (4.6 × 250 mm) col-
umn kept at 35°C, using acetonitrile/water (75:25) as the
mobile phase at 1.2 mL/min.
Biocatalysts stability
Purified proteins or biocatalysts including Eupergit C®
immobilized enzyme preparations were incubated (2 mg/
mL) at 30, 40, 50 and 60°C in pH 6.0, 50 mM sodium
phosphate buffer. Samples were withdrawn after 1 h incu-
bation and assayed for residual activity. Stability assays
were performed in triplicate.
Biocatalysts reutilization
Biocatalyst operational stability (LS-CLEAs and LS-
Eupergit C®) was studied using sequential 1 mL reactions
containing a total enzymatic activity of 4 U/mL of either
WT LS, R360K or Y429N mutant, sucrose (120 g/L) and
xylose (120 g/L) in 50 mM sodium phosphate buffer, pH
6.0, at 37°C under agitation at 1100 rpm. After 3 h of reac-BMC Biotechnology 2009, 9:68 http://www.biomedcentral.com/1472-6750/9/68
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tion, the medium was centrifuged, sucrose conversion
determined and the biocatalysts resuspended in fresh
reaction medium to perform a new reaction. All of the
assays were performed in triplicate.
NMR spectroscopy
The sample was dissolved in D2O (99.96%, Cambridge
isotopes). The spectra were recorded on a Varian Mercury
400 Mhz spectrometer, with TPS as internal reference. 1H-
1H correlated spectroscopy (COSY), total correlation
spectroscopy (TOCSY) and heteronuclear multiple quan-
tum correlation spectroscopy (HMQC) was used to assign
signals. Two dimensional heteronuclear multiple-bond
correlation spectroscopy (HMBC) and two-dimensional
Nuclear Overhauser Effect Spectroscopy (NOESY) were
used to assign inter-residue linkage.
Microscopy
Samples were observed with a Zeiss LSM 510 META con-
focal microscope fitted to a Zeiss Axiovert 200 M. Digital
images were collected in phase contrast mode with a 40×,
NA 0.75, Ph 2.
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